{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:22:09Z","timestamp":1792264929012,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40265-021-01623-w","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T10:53:27Z","timestamp":1635159207000},"page":"2057-2062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Vosoritide: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sean","family":"Duggan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"issue":"1","key":"1623_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, et al. C-Type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019;381(1):25\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"1623_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40272-019-00330-0","volume":"21","author":"O Semler","year":"2019","unstructured":"Semler O, Rehberg M, Mehdiani N, et al. Current and emerging therapeutic options for the management of rare skeletal diseases. Paediatr Drugs. 2019;21(2):95\u2013106.","journal-title":"Paediatr Drugs"},{"issue":"11","key":"1623_CR3","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.3390\/ijms22115573","volume":"22","author":"W Wrobel","year":"2021","unstructured":"Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: a review. Int J Mol Sci. 2021;22(11):5573. https:\/\/doi.org\/10.3390\/ijms22115573.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"1623_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/jpet.114.218560","volume":"353","author":"DJ Wendt","year":"2015","unstructured":"Wendt DJ, Dvorak-Ewell M, Bullens S, et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J Pharmacol Exp Ther. 2015;353(1):132\u201349.","journal-title":"J Pharmacol Exp Ther"},{"key":"1623_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01059-1","author":"ML Chan","year":"2021","unstructured":"Chan ML, Qi Y, Larimore K, et al. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2021. https:\/\/doi.org\/10.1007\/s40262-021-01059-1.","journal-title":"Clin Pharmacokinet"},{"key":"1623_CR6","unstructured":"BioMarin International Limited. Voxzogo: EU summary of product characteristics. 2021. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210826152503\/anx_152503_en.pdf. Accessed 20 Sep 2021."},{"key":"1623_CR7","unstructured":"BioMarin Pharmaceutical. European Commission approves BioMarin's VOXZOGO\u00ae (vosoritide) for the treatment of children with achondroplasia from age 2 until growth plates close [media release]. 27 Aug 2021. https:\/\/investors.biomarin.com\/."},{"key":"1623_CR8","unstructured":"BioMarin Pharmaceutical. BioMarin submits new drug application to U.S. Food and Drug Administration for vosoritide to treat children with achondroplasia [media release]. 21 Aug 2020. http:\/\/www.biomarin.com."},{"key":"1623_CR9","unstructured":"Chugai P. Chugai and BioMarin enter exclusive sublicense agreement on the patent of C- type natriuretic peptide intended for treatment of achondroplasia [media release]. 3 Mar 2016. http:\/\/www.chugai-pharm.co.jp."},{"issue":"6","key":"1623_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","volume":"91","author":"F Lorget","year":"2012","unstructured":"Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91(6):1108\u201314.","journal-title":"Am J Hum Genet"},{"issue":"10252","key":"1623_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396(10252):684\u201392.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1623_CR12","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/S1096-7192(21)00236-5","volume":"132","author":"J Hoover-Fong","year":"2021","unstructured":"Hoover-Fong J, Irving M, Bacino C, et al. Vosoritide for children with achondroplasia: a 60-month update from an ongoing phase 2 clinical trial. Mol Genet Metab. 2021;132(Suppl 1):S101.","journal-title":"Mol Genet Metab"},{"key":"1623_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01287-7","author":"R Savarirayan","year":"2021","unstructured":"Savarirayan R, Tofts L, Irving M et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021. https:\/\/doi.org\/10.1038\/s41436-021-01287-7","journal-title":"Genet Med."},{"issue":"1","key":"1623_CR14","doi-asserted-by":"publisher","first-page":"368504211003782","DOI":"10.1177\/00368504211003782","volume":"104","author":"R Savarirayan","year":"2021","unstructured":"Savarirayan R, Irving M, Maixner W, et al. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery. Sci Prog. 2021;104(1):368504211003782.","journal-title":"Sci Prog"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01623-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T03:21:56Z","timestamp":1637292116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01623-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":14,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01623-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"25 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sean Duggan is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}